CTRI/2021/03/032231尚未招募2 期
A Clinical Study to Evaluate the Therapeutic Safety and Efficacy of Oral Administration of Joshanda (Decoction) of Parsiaoshan (Adiantum capillus-veneris Linn.) in the Management of Hasah al-Kulya (Nephrolithiasis)
Central Council of Unani Medicine New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Clinically/Radiologically diagnosed patients of Hasah al-Kulya (Nephrolithiasis) from size 5 to 8 mm.
- •Patients irrespective of gender.
- •Patients in the age group of 20 to 60 years.
- •Patients who have agreed to sign the informed consent form and follow the protocol.
排除标准
- •Pregnant and Lactating Women.
- •Patients below and above the age of 20 and 60 years respectively.
- •Diabetes Mellitus.
- •Hydronephrosis.
- •Poorly controlled Hypertension.
- •Significant Liver or Renal dysfunction.
- •Cardiovascular disease.
- •Unwillingness or inability to fulfill the protocol.
- •A medical condition that in the investigatorâ??s opinion would interfere the treatment, safety, or adherence to the protocol.
研究者
相似试验
招募中
2 期
Efficacy and Safety of Peptide-derived Hemostatic Material for the Prevention of Post-Esophageal ESD Stenosissuperficial esophageal carcinomaJPRN-jRCTs062220110Oka Shiro20
尚未招募
2 期
Treatment of Constipation(Qabz) naturally with Safoof-i-Banafsha a unani remedyCTRI/2024/06/068794uqman Unani Medical College Hospital and Research Centre
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with senile skidermatoporosis stage I and IIEUCTR2011-002464-24-DEDr. August Wolff GmbH & Co. KG Arzneimittel
已完成
不适用
Clinical study to investigate the efficacy and safety of iliac stenting in patients with peripheral arterial diseasePeripheral arterial disease(PAD), Arteriosclerosis obliterans(ASO)JPRN-UMIN000016264Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan100
招募中
3 期
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib.JPRN-jRCT2031220420Hibi Kazushige324